Perspective: The Case Against Radioiodine Remnant Ablation in Patients with Well-Differentiated Thyroid Carcinoma
Open Access
- 16 July 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (8) , 1395-1397
- https://doi.org/10.2967/jnumed.108.052654
Abstract
We take issue with the stance that postoperative radioiodine remnant ablation should be applied ubiquitously as adjuvant therapy in patients with well-differentiated thyroid carcinoma. In this article, we state the reasons that we believe a compelling case can be made against ablation in most patients.Keywords
This publication has 30 references indexed in Scilit:
- Reducing the Incidence of 131I-Induced Sialadenitis: The Role of PilocarpineJournal of Nuclear Medicine, 2008
- ATA Guidelines: Do Patients with Stage I Thyroid Cancer Benefit From 131I?Thyroid®, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus reportActa Endocrinologica, 2005
- Changing trends in incidence and mortality of thyroid cancer in ScotlandClinical Endocrinology, 2004
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancerNuclear Medicine and Biology, 1993
- The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patientsJournal of Clinical Endocrinology & Metabolism, 1992
- Changing Clinical, Pathologic, Therapeutic, and Survival Patterns in Differentiated Thyroid CarcinomaAnnals of Surgery, 1976